AU2014205483B2 - Non-selective kinase inhibitors - Google Patents

Non-selective kinase inhibitors Download PDF

Info

Publication number
AU2014205483B2
AU2014205483B2 AU2014205483A AU2014205483A AU2014205483B2 AU 2014205483 B2 AU2014205483 B2 AU 2014205483B2 AU 2014205483 A AU2014205483 A AU 2014205483A AU 2014205483 A AU2014205483 A AU 2014205483A AU 2014205483 B2 AU2014205483 B2 AU 2014205483B2
Authority
AU
Australia
Prior art keywords
groups
substituted
unsubstituted
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014205483A
Other languages
English (en)
Other versions
AU2014205483A1 (en
Inventor
Lawrence S. ZISMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PULMOKINE Inc
Gilead Sciences Inc
Original Assignee
PULMOKINE Inc
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PULMOKINE Inc, Gilead Sciences Inc filed Critical PULMOKINE Inc
Publication of AU2014205483A1 publication Critical patent/AU2014205483A1/en
Assigned to PULMOKINE, INC., GILEAD SCIENCES, INC. reassignment PULMOKINE, INC. Request for Assignment Assignors: ZISMAN, LAWRENCE
Application granted granted Critical
Publication of AU2014205483B2 publication Critical patent/AU2014205483B2/en
Priority to AU2018201406A priority Critical patent/AU2018201406A1/en
Priority to AU2020289802A priority patent/AU2020289802A1/en
Priority to AU2023201605A priority patent/AU2023201605B2/en
Priority to AU2024259702A priority patent/AU2024259702A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2014205483A 2013-01-10 2014-01-09 Non-selective kinase inhibitors Active AU2014205483B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2018201406A AU2018201406A1 (en) 2013-01-10 2018-02-27 Non-selective kinase inhibitors
AU2020289802A AU2020289802A1 (en) 2013-01-10 2020-12-17 Non-selective kinase inhibitors
AU2023201605A AU2023201605B2 (en) 2013-01-10 2023-03-15 Non-selective kinase inhibitors
AU2024259702A AU2024259702A1 (en) 2013-01-10 2024-11-04 Non-selective kinase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751217P 2013-01-10 2013-01-10
US61/751,217 2013-01-10
US201361889887P 2013-10-11 2013-10-11
US61/889,887 2013-10-11
PCT/US2014/010778 WO2014110200A1 (en) 2013-01-10 2014-01-09 Non-selective kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201406A Division AU2018201406A1 (en) 2013-01-10 2018-02-27 Non-selective kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2014205483A1 AU2014205483A1 (en) 2015-08-27
AU2014205483B2 true AU2014205483B2 (en) 2017-11-30

Family

ID=51167358

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2014205483A Active AU2014205483B2 (en) 2013-01-10 2014-01-09 Non-selective kinase inhibitors
AU2018201406A Abandoned AU2018201406A1 (en) 2013-01-10 2018-02-27 Non-selective kinase inhibitors
AU2020289802A Abandoned AU2020289802A1 (en) 2013-01-10 2020-12-17 Non-selective kinase inhibitors
AU2023201605A Active AU2023201605B2 (en) 2013-01-10 2023-03-15 Non-selective kinase inhibitors
AU2024259702A Abandoned AU2024259702A1 (en) 2013-01-10 2024-11-04 Non-selective kinase inhibitors

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2018201406A Abandoned AU2018201406A1 (en) 2013-01-10 2018-02-27 Non-selective kinase inhibitors
AU2020289802A Abandoned AU2020289802A1 (en) 2013-01-10 2020-12-17 Non-selective kinase inhibitors
AU2023201605A Active AU2023201605B2 (en) 2013-01-10 2023-03-15 Non-selective kinase inhibitors
AU2024259702A Abandoned AU2024259702A1 (en) 2013-01-10 2024-11-04 Non-selective kinase inhibitors

Country Status (9)

Country Link
US (3) US9815815B2 (enExample)
EP (1) EP3007689B1 (enExample)
JP (2) JP6387488B2 (enExample)
CN (2) CN109568319A (enExample)
AU (5) AU2014205483B2 (enExample)
CA (1) CA2897651C (enExample)
DK (1) DK3007689T3 (enExample)
ES (1) ES2675720T3 (enExample)
WO (1) WO2014110200A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
JP2016506417A (ja) * 2013-01-10 2016-03-03 プルモキネ、インコーポレイテッド キナーゼ阻害剤の治療指標
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CA3280124A1 (en) * 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
ES2959419T3 (es) * 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
US20200033346A1 (en) * 2017-03-16 2020-01-30 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic and therapeutic methods for kras positive cancers
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
CN109574296B (zh) * 2018-11-27 2021-05-07 合肥工业大学 一种从含蟹肉蛋白废水中回收蛋白的方法
US11413289B2 (en) * 2019-05-16 2022-08-16 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
KR20240006513A (ko) * 2021-05-07 2024-01-15 지비002 인코포레이티드 N-3-[(1s)-1-[6-(3,4-다이메톡시페닐)피라진-2-일]아미노에틸]페닐-5-메틸피리딘-3-카복사마이드의 결정질 형태 및 관련 생성물 및 방법
US20250129067A1 (en) 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
EP4568692A1 (en) 2022-08-10 2025-06-18 GB002, Inc. Tyrosine kinase inhibitor and activin type 2 receptor antagonist combination therapy for treating pulmonary arterial hypertension (pah)
WO2026151681A1 (en) 2025-01-09 2026-07-16 Gb002, Inc. Combination therapy for treating interstitial lung disease
CN119930631B (zh) * 2025-04-07 2025-06-24 山东大学 一种靶向ddr1受体的化合物及其衍生的放射性示踪剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118401A (en) 1977-10-19 1978-10-03 American Hoechst Corporation Preparation of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid and precursors therefor
JPS5488231A (en) 1977-12-22 1979-07-13 Sumitomo Chem Co Ltd 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5648369A (en) * 1991-11-20 1997-07-15 University Of Kentucky Research Foundation Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists
SK27198A3 (en) 1995-08-30 1998-09-09 Bayer Ag Acylaminosalicylic acid amides and their uses as pesticides
JPH09268169A (ja) 1996-04-01 1997-10-14 Otsuka Chem Co Ltd サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
CA2382821A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6451830B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity
WO2001029025A2 (en) 1999-10-19 2001-04-26 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778417B2 (en) 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CA2486183C (en) 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
ATE457025T1 (de) 2002-05-23 2010-02-15 Cytopia Res Pty Ltd Kinaseinhibitoren
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
ATE408583T1 (de) 2002-05-23 2008-10-15 Cohen Ben Z Medizinisch genaues pumpsystem
DK1522314T3 (da) 2002-06-26 2014-05-26 Ono Pharmaceutical Co Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse
JP2005538975A (ja) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
EP1542699A4 (en) 2002-07-15 2009-03-25 Myriad Genetics Inc COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
JP4942297B2 (ja) 2002-10-25 2012-05-30 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050026879A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
ATE455546T1 (de) 2003-08-06 2010-02-15 Vertex Pharma Aminotriazol-verbindungen als proteinkinase- hemmer
JP4823914B2 (ja) 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
PT1689715E (pt) 2003-12-03 2011-05-16 Ym Biosciences Australia Pty Inibidores da tubulina
GB2423083B (en) * 2003-12-03 2007-07-11 Cytopia Res Pty Ltd Azole-based kinase inhibitors
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
US20080268460A1 (en) 2004-05-20 2008-10-30 Wyeth Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases
JP2006111553A (ja) 2004-10-13 2006-04-27 Dainippon Sumitomo Pharma Co Ltd スルホニルオキシインドール誘導体及びそれを含有する医薬組成物
CA2628847A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl ureas for treating pulmonary hypertension
WO2007087575A2 (en) 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
WO2007124382A2 (en) 2006-04-19 2007-11-01 Novartis Vaccines And Diagnostics, Inc. Inhaled imipenem
CA2686378C (en) 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
BRPI0811516A2 (pt) 2007-05-04 2014-11-18 Irm Llc Compostos e composições como inibidores de c-kit e pdgfr cinase
EA017392B1 (ru) 2007-08-22 2012-12-28 Айрм Ллк Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ
AU2008289037B2 (en) 2007-08-22 2012-03-01 Novartis Ag 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
HRP20120457T1 (hr) 2007-12-20 2012-06-30 Bayer Pharma Aktiengesellschaft 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba
KR20110053354A (ko) 2008-08-13 2011-05-20 노파르티스 아게 폐동맥 고혈압의 치료
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
WO2010132827A1 (en) 2009-05-15 2010-11-18 Bend Research, Inc. Low-molecular dextran for powder inhalations
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
SG195038A1 (en) 2011-05-19 2013-12-30 Savara Inc Dry powder vancomycin compositions and associated methods
US8569283B2 (en) 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
JP2016506417A (ja) * 2013-01-10 2016-03-03 プルモキネ、インコーポレイテッド キナーゼ阻害剤の治療指標
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
WO2015179369A1 (en) 2014-05-20 2015-11-26 Infinity Pharmaceuticals, Inc. Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity

Also Published As

Publication number Publication date
AU2014205483A1 (en) 2015-08-27
US10532994B2 (en) 2020-01-14
EP3007689A4 (en) 2016-07-13
JP6547042B2 (ja) 2019-07-17
EP3007689A1 (en) 2016-04-20
US20190248761A1 (en) 2019-08-15
AU2023201605B2 (en) 2024-08-29
JP6387488B2 (ja) 2018-09-12
US20150353527A1 (en) 2015-12-10
WO2014110200A1 (en) 2014-07-17
CA2897651A1 (en) 2014-07-17
US20180162837A1 (en) 2018-06-14
EP3007689B1 (en) 2018-03-07
DK3007689T3 (en) 2018-06-14
AU2020289802A1 (en) 2021-01-21
ES2675720T3 (es) 2018-07-12
AU2023201605A1 (en) 2023-04-13
US10246438B2 (en) 2019-04-02
US9815815B2 (en) 2017-11-14
JP2018158931A (ja) 2018-10-11
JP2016506418A (ja) 2016-03-03
CA2897651C (en) 2021-09-21
CN105142624A (zh) 2015-12-09
AU2018201406A1 (en) 2018-03-15
CN109568319A (zh) 2019-04-05
AU2024259702A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
AU2023201605B2 (en) Non-selective kinase inhibitors
AU2014331796B2 (en) Spray dry formulations
WO2014110198A2 (en) Therapeutic indications of kinase inhibitors
HK40036372B (zh) 喷雾干燥制剂
HK40036372A (en) Spray dry formulations
HK40009913A (en) Non-selective kinase inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PULMOKINE, INC.; GILEAD SCIENCES, INC.

Free format text: FORMER APPLICANT(S): ZISMAN, LAWRENCE

FGA Letters patent sealed or granted (standard patent)